Natural killer cytotoxicity in the diagnosis of immune dysfunction: Criteria for a reproducible assay

Journal of Clinical Laboratory Analysis

Volumn 4, Issue 2, 1990, Pages 102-114

  Whiteside, Theresa L ^a,b   Bryant, John ^a,d   Herberman, Ronald B ^a,b   Day, Roger ^a,c  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

Author keywords

human NK cells; Laboratory evaluation of NK function; NK assays; quality control; serial monitoring of NK cells; statistical analysis of NK activity

Indexed keywords

ARTICLE; HUMAN; IMMUNOPATHOLOGY; NATURAL KILLER CELL;

EID: 0025608452     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.1860040207     Document Type: Article

References (56)

1. Natural killer cells. Their role in defense against disease
2. Human natural killer cells: Biologic and pathologic aspects
3. The role of natural killer cells in human disease
4. Characterization of human granular lymphocyte subpopulations expressing NHK‐1 (Leu‐7 and Leu‐11) antigens in the blood and lymphoid tissues from fetuses, neonates and adults
5. Characteristics of human large granular lymphocytes and their relationship to natural killer (NK) cells
6. The human NK cell: A short review and hypothesis of NK recognition
7. Heterogeneity of natural killer cells
8. Characterization of cytotoxic cells generated from bone marrow culture
9. Generation of NK cell activity from human bone marrow
10. The IL2 receptor chain (p70): Role in mediating signals for LAK, NK, and proliferative activities
11. A functional comparison of human Fc receptor‐bearing lymphocytes active in natural cytotoxicity and antibody‐dependent cellular cytotoxicity
12. Interaction of Fc receptor (CD 16) with ligands induces transcription of IL2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells
13. The effect of natural killer cells on the development of syngeneic hematopoietic progenilors
14. Capacity of human large granular lymphocytes (LGL) to produce multiple lymphokines: Interleukin 2, Interferon, and colony stimulating factor
15. Inhibition of bone marrow pleuripotent hematapoietic stem cells by large granular lymphocytes
16. Effect of natural killer cells on syngeneic bone marrow: In vitro and in vivo studies demonstrating graft failure due to NK cells in an identical twin treated by bone marrow transplantation
17. Evidence for the role of natural immunity and the control of metastatic spread of head and neck cancer
18. Depressed natural killer cell activity in patients with hepatacellular carcinoma: In vitro effects of interferon and levamisol
19. Interleukin 2 induction of lymphokine‐activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. Feasibility of LAK generation in adult patients with active disease and in remission
20. Cell profile in leukemia patients
21. Familial occurrence of breast cancer is associated with reduced natural killer cytotoxicity
22. Natural killer cell activity in head and neck cancer: A clinical assessment
23. Prognostic risk assessment in primary breast cancer by behavioral and immunological parameters
24. Changes in peripheral T cell subsets and natural killer cytotoxicity in relation to colorectal cancer surgery
25. In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin 2 LAK cell therapy
26. Depression of natural killer cytotoxicity after in vivo administration of recombinant leukocyte interferon
27. Characterization of natural killer cells with anti‐leukemia activity following allogeneic bone marrow transplantation
28. Natural cytotoxic activity against cytomegalavirus‐infected target cells following marrow transplantation
29. Persistently low natural killer cell activity: Immunological, hormonal and psychological correlates
30. Natural killer cell‐mediated activity in mixed connective tissue disease and its response to induction by interleukin 2
31. Depletion of microspheres coated with T‐lymphocyte specific monoclonal antibodies
32. Isolation of human natural killer cells by density gradient centrifugation
33. Spontaneous human lymphocyte‐mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity
34. Cryopreservation of human lymphocytes for assessment of lymphocyte subsets and natural killer cytotoxicity
35. Modulation of natural killer cell activity by serum from cancer patients. Preliminary results of a study of patients with colorectal adenocarcinoma or other types of cancer
36. An improved colorimetric assay for T cel1 cytotoxicity in vitro
37. Mechanism of cell‐mediated cytotoxicity at the single cell level. 1. Estimation of cytotoxic T lymphocyte frequency and relative lytic efficiency
38. Cell‐mediated cytotoxic reactions
39. Analysis fo cytostatic/cytotoxic lymphokines: relationship of natural killer cytotoxic factor to recombinant lymphotoxin, recombinant tumor necrosis factor and leukoregulin
40. Characteristics and uses of natural killer cells
41. The relationship of CD 16 (Leu 11) and Leu 19 (NKH1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes
42. Natural killer cell activity as a marker of immune dysfunction in the chronic fatigue syndrome (abst.)
43. A new immunodeficiency disorder in humans involving NK cells
44. Tissue distribution of human NK cells studied with anti‐Leu 7 monoclonal antibody
45. Distribution of natural killer cell activity in peripheral blood, cord blood, thymus lymph nodes and spleen, and the effect of in vitro treatment with interferon preparations
46. Natural killer cell
47. Circadian changes in human natural killer cell activity
48. The assessment of natural killer cell activity in cancer patients